Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Kenjiro Kamezaki, Yoshikane Kikushige, Akihiko Numata, Toshihiro Miyamoto, K. Takase, H. Henzan, K. Aoki, Koji Kato, Atsushi Nonami, T. Kamimura, F. Arima, Katsuto Takenaka, N. Harada, T. Fukuda, S. Hayashi, Y. Ohno, T. Eto, M. Harada, K. Nagafuji

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). There was no difference in the number of CD34+ cells among PBSC between the non-rituximab and the rituximab groups. Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. Despite the short follow-up, there was no significant difference in progression-free survival between the two groups. These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab.

Original languageEnglish
Pages (from-to)523-527
Number of pages5
JournalBone Marrow Transplantation
Volume39
Issue number9
DOIs
Publication statusPublished - May 1 2007

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Integrin alpha4beta1
Transplants
Peripheral Blood Stem Cell Transplantation
Rituximab
Peripheral Blood Stem Cells
Disease-Free Survival
Neutrophils
B-Lymphocytes
Blood Platelets
Cell Count
Transplantation
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. / Kamezaki, Kenjiro; Kikushige, Yoshikane; Numata, Akihiko; Miyamoto, Toshihiro; Takase, K.; Henzan, H.; Aoki, K.; Kato, Koji; Nonami, Atsushi; Kamimura, T.; Arima, F.; Takenaka, Katsuto; Harada, N.; Fukuda, T.; Hayashi, S.; Ohno, Y.; Eto, T.; Harada, M.; Nagafuji, K.

In: Bone Marrow Transplantation, Vol. 39, No. 9, 01.05.2007, p. 523-527.

Research output: Contribution to journalArticle

Kamezaki, K, Kikushige, Y, Numata, A, Miyamoto, T, Takase, K, Henzan, H, Aoki, K, Kato, K, Nonami, A, Kamimura, T, Arima, F, Takenaka, K, Harada, N, Fukuda, T, Hayashi, S, Ohno, Y, Eto, T, Harada, M & Nagafuji, K 2007, 'Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma', Bone Marrow Transplantation, vol. 39, no. 9, pp. 523-527. https://doi.org/10.1038/sj.bmt.1705649
Kamezaki, Kenjiro ; Kikushige, Yoshikane ; Numata, Akihiko ; Miyamoto, Toshihiro ; Takase, K. ; Henzan, H. ; Aoki, K. ; Kato, Koji ; Nonami, Atsushi ; Kamimura, T. ; Arima, F. ; Takenaka, Katsuto ; Harada, N. ; Fukuda, T. ; Hayashi, S. ; Ohno, Y. ; Eto, T. ; Harada, M. ; Nagafuji, K. / Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. In: Bone Marrow Transplantation. 2007 ; Vol. 39, No. 9. pp. 523-527.
@article{afd6a52c6c0548fab87b0740478462d5,
title = "Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma",
abstract = "To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). There was no difference in the number of CD34+ cells among PBSC between the non-rituximab and the rituximab groups. Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. Despite the short follow-up, there was no significant difference in progression-free survival between the two groups. These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab.",
author = "Kenjiro Kamezaki and Yoshikane Kikushige and Akihiko Numata and Toshihiro Miyamoto and K. Takase and H. Henzan and K. Aoki and Koji Kato and Atsushi Nonami and T. Kamimura and F. Arima and Katsuto Takenaka and N. Harada and T. Fukuda and S. Hayashi and Y. Ohno and T. Eto and M. Harada and K. Nagafuji",
year = "2007",
month = "5",
day = "1",
doi = "10.1038/sj.bmt.1705649",
language = "English",
volume = "39",
pages = "523--527",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

AU - Kamezaki, Kenjiro

AU - Kikushige, Yoshikane

AU - Numata, Akihiko

AU - Miyamoto, Toshihiro

AU - Takase, K.

AU - Henzan, H.

AU - Aoki, K.

AU - Kato, Koji

AU - Nonami, Atsushi

AU - Kamimura, T.

AU - Arima, F.

AU - Takenaka, Katsuto

AU - Harada, N.

AU - Fukuda, T.

AU - Hayashi, S.

AU - Ohno, Y.

AU - Eto, T.

AU - Harada, M.

AU - Nagafuji, K.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). There was no difference in the number of CD34+ cells among PBSC between the non-rituximab and the rituximab groups. Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. Despite the short follow-up, there was no significant difference in progression-free survival between the two groups. These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab.

AB - To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). There was no difference in the number of CD34+ cells among PBSC between the non-rituximab and the rituximab groups. Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. Despite the short follow-up, there was no significant difference in progression-free survival between the two groups. These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab.

UR - http://www.scopus.com/inward/record.url?scp=34247394534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247394534&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705649

DO - 10.1038/sj.bmt.1705649

M3 - Article

C2 - 17369863

AN - SCOPUS:34247394534

VL - 39

SP - 523

EP - 527

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -